ALLMedicine™ Dry Skin Center

Nov 18th, 2021 - Protocol Outline Protocol Title: Effects of a seven-day BASIS™ supplementation on menopausal syndromes and measurements of the urinary vitamin B3 and estradiol levels in pre-, peri- and post-menopause. I. Abstract Context: Nicotinamide adenine din...

Nov 17th, 2021 - This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20...

Nov 16th, 2021 - Hand eczema is a common inflammatory skin disorder in both adolescence and adulthood. We sought to assess the lifetime prevalence of hand eczema and associated exogenous and endogenous risk factors among adolescents in Germany. This was a cross-se...

Nov 8th, 2021 - Filaggrin-derived natural moisturizing factors (NMF) play an important role in skin barrier function and in atopic dermatitis (AD). Its deficiency is associated with dry skin and increased surface pH. Studies on childhood environmental exposures a...

Nov 8th, 2021 - Clinical studies have clarified the usefulness of moisturizers for dry skin diseases. However, few reports exist on the appropriate application of moisturizers with respect to the skin physiological functions. To clarify the optimal moisturizer ap...

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

Nov 18th, 2021 - Protocol Outline Protocol Title: Effects of a seven-day BASIS™ supplementation on menopausal syndromes and measurements of the urinary vitamin B3 and estradiol levels in pre-, peri- and post-menopause. I. Abstract Context: Nicotinamide adenine din...

Nov 17th, 2021 - This is a research study to find out if a drug called, osimertinib, is safe and effective in treating advanced Non-Small Cell Lung Cancer (NSCLC) by targeting the treatment of epidermal growth factor receptor (EGFR) mutation exon 18 G719X, exon 20...

May 21st, 2021 - Carpal tunnel syndrome is a clinical picture that occurs with a group of symptoms and signs as a result of compression and compression in the carpal tunnel where the median nerve passes to the wrist. Another name is hand-wrist canal disease, the m...

Apr 8th, 2021 - Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching, oozing and crusting, redness, skin erosion and dry skin. This study will evaluate how well upadacitinib compared to placebo (no medicine) works...

Feb 21st, 2021 - This study is being conducted to address key gaps in current knowledge and set the stage for rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure to radiation before overt signs/symptoms appear), and/or tre...

Nov 19th, 2021 - The FDA granted accelerated approval to the first drug to spur growth in kids with the most common form of dwarfism, the agency announced on Friday. Vosoritide (Voxzogo), a once-daily injectable treatment, is indicated for children 5 years and old...

Oct 27th, 2021 - Transcript: Erminia Massarelli, MD, MS, PhD: The mechanism of action of mobocertinib [Exkivity] is an irreversible EGFR tyrosine kinase inhibitor. However, it differs from osimertinib [Tagrisso], which is currently approved for exon 19 and21 muta...

Oct 6th, 2021 - Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies. BRAF and MEK inhibitors have numerous common side effects that can some...

Oct 6th, 2021 - Biliary tract cancers are an aggressive group of malignancies that historically have been very challenging to treat because of their anatomical location and limited responsiveness to systemic therapy.1-3 Biliary cancers arise from the epithelial l...

Sep 19th, 2021 - Adagrasib (MRTX849) alone or in combination with cetuximab (Erbitux) elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer (CRC), according to findings from the phase 1/2 KRYSTAL-...